WallStSmart

iRhythm Technologies Inc (IRTC)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 7473% more annual revenue ($56.58B vs $747.14M). NVS leads profitability with a 23.9% profit margin vs -6.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

IRTC

Avoid

31

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 4.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.31

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRTCSignificantly Overvalued (-55.9%)

Margin of Safety

-55.9%

Fair Value

$97.56

Current Price

$129.16

$31.60 premium

UndervaluedFair: $97.56Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRTC1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.1%8/10

Revenue surging 27.1% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

IRTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
4.2%3/10

Operating margin of 4.2%

Price/BookValuation
27.3x2/10

Trading at 27.3x book value

Return on EquityProfitability
-36.6%2/10

ROE of -36.6% — below average capital efficiency

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : IRTC

The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 27.1% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : IRTC

The primary concerns for IRTC are EPS Growth, Operating Margin, Price/Book.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

IRTC profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

IRTC carries more volatility with a beta of 1.18 — expect wider price swings.

IRTC is growing revenue faster at 27.1% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 31/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

iRhythm Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?